Korro Bio

Korro Bio is a clinical-stage biopharmaceutical company developing genetic medicines based on RNA editing for rare and highly prevalent diseases. Its proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform uses GalNAc-conjugated oligonucleotides to recruit endogenous adenosine deaminase acting on RNA for precise, transient single-base edits, an approach designed to avoid the permanent DNA cuts associated with gene editing. The company's lead programme, KRRO-121, is in the Phase 1/2 ANCHOR trial in healthy volunteers for hyperammonemia associated with urea cycle disorders and hepatic encephalopathy; KRRO-111 is in late preclinical development for alpha-1 antitrypsin deficiency, targeting both the lung and liver manifestations of the disease, with a regulatory submission and first-in-human entry guided for the first half of 2027. Korro also has discovery programmes in neurologic and pain indications and a collaboration with Novo Nordisk covering cardiometabolic disease. The company is headquartered in Cambridge, Massachusetts and trades on the Nasdaq Global Market under the ticker KRRO.